FormWeb • lamiVUDine-tenofovir disoproxil fumarate

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

tenofovir disoproxil fumarate-lamiVUDine

lamiVUDine-tenofovir disoproxil fumarate

Non-formulary
Therapeutic Interchange

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Cimduo	TABLET, ORAL	300 mg-300 mg
Temixys	TABLET, ORAL	300 mg-300 mg

Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

lamiVUDine-tenofovir disoproxil fumarate (Cimduo)

300 mg-300 mg oral tablet

lamiVUDine (Epivir) and tenofovir disoproxil fumarate (Viread)

ONE 300 mg lamiVUDine oral tablet PLUS ONE 300 mg tenofovir disoproxil fumarate oral tablet

lamiVUDine-tenofovir disoproxil fumarate (Temixys)

300 mg-300 mg oral tablet

lamiVUDine (Epivir) and tenofovir disoproxil fumarate (Viread)

ONE 300 mg lamiVUDine oral tablet PLUS ONE 300 mg tenofovir disoproxil fumarate oral tablet

Reviewed: 28 Aug 2018 (Cimduo), and 28 May 19 (Temixys)

Last updated: May. 28, 2019

Black Box Warning: Post Treatment Acute Exacerbation of Hepatitis B

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.